



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Datasheet for S000-04**Streptavidin Cy3 Conjugated****Overview**

Description:	Streptavidin CY3 Conjugated - S000-04
Item No.:	S000-04
Size:	1 mg
Applications:	Dot Blot, IF, IHC, Multiplex

Product Details

Background:	Streptavidin is isolated from bacteria, <i>Streptomyces avidinii</i> , and has an exceptionally high binding affinity for B7 (biotin). Rockland offers streptavidin in unconjugated and conjugated forms for common immunoassays including ELISA, western blotting, immunohistochemistry. Streptavidin is a tetrameric protein capable of binding 4 biotin groups to each molecule of streptavidin. While streptavidin has identical binding properties as avidin, it lacks the glycoprotein portion of the molecule and therefore shows less non-specific binding. Streptavidin is a slightly smaller molecule with a molecular weight of approximately 53.6 kDa. The sequence of avidin only shows 30% homology with streptavidin, and anti-avidin and anti-streptavidin antibodies are not immunologically cross reactive. Rockland conjugates a broad group of secondary antibodies to many of the classic fluorescent markers including fluorescein, rhodamine, Texas Red, CyDyes™ and Phycoerythrin (RPE). All of the conjugates are ideal for various immunofluorescence based assays including fluorescent western blotting, immunofluorescence microscopy, FLISA, and more. Rockland also produces many next generation fluorochrome dyes designed for detection of primary antibodies in multiplex, multi-color analysis.
Synonyms:	SA, S avidin, streptococcus avidin, Streptavidin Cy3 Conjugated
Conjugate:	Cy3™
F/P Ratio:	4.1

Target Details

Purity/Specificity:	This product was prepared from chromatographically pure Streptavidin. Assay by immuno-electrophoresis resulted in a single precipitin arc against anti-Streptavidin.
----------------------------	--

Application Details

Tested Applications:	Dot Blot
Suggested Applications:	IF, IHC, Multiplex (Based on references)
Application Note:	Streptavidin CY3 conjugated has been tested by dot blot and is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
FC:	1:500 - 1:2,500
FLISA:	1:10,000 - 1:50,000
IF:	1:1,000 - 1:5,000

Formulation

Physical State:	Lyophilized
Concentration:	1.0 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Reconstitution Volume:	1.0 mL
Reconstitution Buffer:	Restore with deionized water (or equivalent)

Shipping & Handling


Shipping Condition:	Ambient
Storage Condition:	Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images




Bottle

Streptavidin CY3 Conjugated




Immunofluorescence Microscopy

Loss of Siglec-E abrogates responsiveness to polySia and enhances LPS-induced activation. **a** Compared to wildtype BV2 cells (Siglec-E^{+/+}), the immunoreactivity of Siglec-E (red), but not polySia (green) is abolished by CRISPR/spCas9-mediated knockout of Siglec-E (Siglec-E^{-/-}, clone D19). Nuclear counterstain with DAPI (blue). Scale bar, 50 μ m. Cells were incubated with primary antibodies and for with HRP-conjugated anti-sheep IgG for the detection of Siglec-E-specific antibody, followed by incubation, then enzymatically produced biotin precipitate was detected by Cy3-conjugated streptavidin (1:1.000 p/n S000-04), before fluorescently labeled secondary antibodies were added. Fig. 6. PMID: 32725371.



Immunofluorescence Microscopy

Targeting the tumor vasculature with selected cystine-knot miniproteins. a Specific binding of MC-FN-010 to tissue sections derived from the human U-87 MG glioblastoma cell line grown as mouse xenograft tumor. Representative immunofluorescence staining of U-87 MG tumor tissues and normal mouse brain with EDB ligand MC-FN-010 and negative control MC-FN-0115. Tissue sections (6 μm) were stained with tetramerized cystine-knot miniprotein-biotin/streptavidin-Cy3 complex (red) and an anti-CD31 antibody to visualize vasculature (green). Scale bars, 100 μm. b In vivo and ex vivo imaging of U-87 MG bearing mice. Tumors derived from human U-87 MG cells injected s.c. in flanks of mice were imaged after i.v. application of 3.34 nmol AF680-(MC-FN-010)3, AF680-(MC-FN-016)3 (EDB binder), and control AF680-(MC-FN-0115)3. Mice (n = 3) were stratified according to their tumor sizes. Fig. 4. PMID: 31941901.



Immunohistochemistry

Maternal decompensation rescues defects in extraembryonic tissues and growth restriction of Cmas^{-/-} mice. Pregnant Cmas^{+/-} mice were treated at E4.5 and E6.5 either with PBS (n = 3) or CVF (n = 3) to deplete maternal C3. E8.5 sagittal uteri paraffin sections (A and B). (A) The reduced size of the EPC and lack of a CP in Cmas^{-/-} embryos of PBS-treated mothers was reverted to the control phenotype upon CVF treatment, as visualized by immunohistochemical cytokeratin-8 staining. The lack of CEBPB reactivity (indirect immunofluorescence) in Cmas^{-/-} embryos of PBS-treated mothers was restored upon CVF treatment. PNA reactivity documenting the loss of cell surface sialylation was maintained in Cmas^{-/-} embryos of PBS- and CVF-treated mothers, indicating that the asialo phenotype was not influenced by CVF. Representative images of experiments with PBS-treated mice: control, n = 5; Cmas^{-/-}, n = 3 embryos; CVF treated mice: control, n = 5; Cmas^{-/-}, n = 4 embryos. (B) Collagen IV indirect immunofluorescence (red). Thickened RM (arrow) in Cmas^{-/-} embryos of PBS-treated mothers was converted to the control phenotype upon CVF treatment. Parietal endoderm is marked by arrowheads. Nuclei shown in white were stained with DAPI. (C) Quantification of RM thickness measured on collagen IV immunofluorescence images at the anti-mesometrial pole (PBS: control, n = 6; Cmas^{-/-}, n = 3 embryos; CVF: control, n = 5; Cmas^{-/-}, n = 4 embryos). (D) Mean of fetal size as measured by the sum of the areas of the amniotic cavity, exocoelomic cavity, ectoplacental cavity, and embryo proper in (μm²/105) (PBS: control, n = 5; Cmas^{-/-}, n = 4 embryos; CVF: control, n = 5; Cmas^{-/-}, n = 3 embryos); Statistical analyses by 1-way ANOVA with Newman-Keuls post test (*P < 0.05; **P < 0.01; ***P < 0.001). Error bars indicate SD (C and D). Primary antibodies were applied. Cebpb antibody was preincubated with biotinylated anti-mouse IgG Fab fragments prior to use. Secondary antibodies added. Biotinylation was detected using streptavidin-HRP at 1:500, and the signal was amplified by biotin tyramide. Streptavidin-Cy3, (1:500, p/n S000-04) served as the detection system. Cytokeratin-8 detected using the HRP anti-rat IgG conjugate. Figure 7. PMID: 30382946.

References

- Thiesler H et al. Polysialic acid and polysialic acid receptors as regulators of microglia and macrophage activation. *Cell Mol Life Sci.* (2021)
- Lui BG, Salomon N, Wüsthube-Lausch J, et al. Targeting the tumor vasculature with engineered cystine-knot miniproteins. *Nat Commun.* (2020)
- Abeln M et al. Sialic acid is a critical fetal defense against maternal complement attack. *J Clin Invest.* (2019)
- Van Sluis et al. A localized nucleolar DNA damage response facilitates recruitment of the homology-directed repair machinery independent of cell cycle stage. *Genes & Development* (2015)
- Shen, CI et al. The infection of chicken tracheal epithelial cells with a H6N1 avian influenza virus. *PloS One* (2011)
- Fessing, MY et al. p63 regulates Satb1 to control tissue-specific chromatin remodeling during development of the epidermis. *The Journal of Cell Biology* (2011)
- Huggenberger, R. et al. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. *The Journal of Experimental Medicine* (2010)
- Sow, FB. et al. Laser Capture Microdissection Revisited as a Tool for Transcriptomic Analysis: Application of an Excel-Based qPCR Preparation Software (PREXCEL-Q). *International Journal of Biomedical Science : Ijbs* (2009)
- Gallup, JM. et al. New quick method for isolating RNA from laser captured cells stained by immunofluorescent immunohistochemistry; RNA suitable for direct use in fluorogenic TaqMan one-step real-time RT-PCR. *Biological Procedures Online* (2005)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.